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ABSTRACT
To develop response criteria for juvenile dermatomyositis
(DM). We analysed the performance of 312 definitions
that used core set measures from either the International
Myositis Assessment and Clinical Studies Group (IMACS)
or the Paediatric Rheumatology International Trials
Organisation (PRINTO) and were derived from natural
history data and a conjoint analysis survey. They were
further validated using data from the PRINTO trial
of prednisone alone compared to prednisone with
methotrexate or cyclosporine and the Rituximab in
Myositis (RIM) trial. At a consensus conference, experts
considered 14 top candidate criteria based on their
performance characteristics and clinical face validity,
using nominal group technique. Consensus was reached
for a conjoint analysis–based continuous model with a
total improvement score of 0–100, using absolute per
cent change in core set measures of minimal (≥30),
moderate (≥45), and major (≥70) improvement. The
same criteria were chosen for adult DM/polymyositis,
with differing thresholds for improvement. The sensitivity
and specificity were 89% and 91–98% for minimal
improvement, 92–94% and 94–99% for moderate
improvement, and 91–98% and 85–86% for major
improvement, respectively, in juvenile DM patient cohorts
using the IMACS and PRINTO core set measures.
These criteria were validated in the PRINTO trial for
differentiating between treatment arms for minimal and
moderate improvement (p=0.009–0.057) and in the
RIM trial for significantly differentiating the physician’s
rating for improvement (p<0.006). The response criteria
for juvenile DM consisted of a conjoint analysis–based
model using a continuous improvement score based on
absolute per cent change in core set measures, with
thresholds for minimal, moderate, and major
improvement.
Juvenile dermatomyositis (DM) is a systemic auto-
immune disease characterised by chronic skeletal
muscle inflammation and weakness. Core set mea-
sures to assess juvenile DM disease activity have
been established and validated by the International
Myositis Assessment and Clinical Studies Group
(IMACS) and the Paediatric Rheumatology
International Trials Organisation (PRINTO), with
provisional endorsement by the American College
of Rheumatology and the European League Against
This criteria set has been approved by the American College of Rheumatology (ACR) Board of Directors and
the European League Against Rheumatism (EULAR) Executive Committee. This signifies that the criteria set
has been quantitatively validated using patient data, and it has undergone validation based on an
independent data set. All ACR/EULAR-approved criteria sets are expected to undergo intermittent updates.
The ACR is an independent, professional, medical and scientific society that does not guarantee, warrant,
or endorse any commercial product or service.
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Rheumatism.1–6 Both core sets include physician and parent
global activity, muscle strength, and physical function. IMACS
also includes the most abnormal serum muscle enzyme value
and extramuscular global activity, whereas PRINTO includes
instead a health-related quality of life measure, the Child Health
Questionnaire7 and a global activity score, the Disease Activity
Score.8 IMACS measures muscle strength using manual muscle
testing, and PRINTO measures muscle strength using the
Childhood Myositis Assessment Scale.1 2 5
Combinations of these measures to determine clinical
improvement were developed to enhance the sensitivity of
responses and decrease the sample sizes needed, by using large
prospective natural history data sets and expert clinician consen-
sus as the gold standard. For both PRINTO and IMACS, at least
20% improvement in 3 of 6 core set measures with no more
than 1 or 2 worsening (which cannot be muscle strength) had
been established as preliminary response criteria, and additional
combinations of improvement in the core set measures serve as
secondary response criteria.9 10 PRINTO adapted its top criteria
for minimal clinical improvement to moderate and major
improvement by using cutoffs of 50% and 70%, similar to the
improvement criteria for juvenile idiopathic arthritis ( JIA).11–13
Although the preliminary response criteria for juvenile DM
advanced the assessment of patients and their responses to treat-
ment, those criteria were limited by differences in the core set
measures and final consensus response criteria between IMACS
and PRINTO, a lack of randomised controlled trial data for full
validation, and inadequate exploration of more sensitive
approaches using hybrid or continuous methods.14 The prelimin-
ary response criteria also considered each core set measure equally
rather than differentially weighting them. However, most myositis
experts agree that some core set measures are more important,
such as physician global activity and muscle strength.3 15 For
PRINTO studies, physician global evaluation of disease activity,
muscle strength, and parent global evaluation of the child’s overall
well-being were weighted as the most important core set measures
in a logistic regression analysis.3 10 Moreover, the preliminary
response criteria did not validate criteria for moderate or major
improvement. There is, therefore, a clear need to have standar-
dised improvement criteria for all levels of improvement in future
clinical trials, similar to the standardized criteria developed for
rheumatoid arthritis (RA) and JIA.
For these reasons, IMACS and PRINTO engaged in a joint
effort to develop fully validated response criteria for juvenile
DM, including criteria for minimal, moderate, and major clin-
ical response. This report focuses on the consensus conference
in which the top candidate definitions of response leading to
the final juvenile DM response criteria were considered.
METHODS
In previous reports,16 17 we described the methodology used a) to
create patient profiles using natural history data and obtain expert
consensus on minimal, moderate, and major improvement,16 b) to
determine differential weights of the core set measures using con-
joint analysis, and c) to draft six types of candidate definitions for
response criteria using the myositis expert survey on thresholds of
improvement and data-driven methods, such as logistic regression
and conjoint analysis (table 1).
Conjoint analysis is a choice modeling or discrete choice
experiment, which is a valid methodology for developing com-
posite criteria and has been used recently in rheumatology.19–22
In the conjoint analysis surveys administered using 1000Minds
online software,23 experts were presented with pairs of hypo-
thetical patient scenarios; each patient had different levels of
improvement in the same 2 core set measures, assuming other
core set measures remained the same. Experts rated which of
the 2 scenarios had greater improvement. Based on the rater’s
response, the relative weights of core set measures and their
levels of improvement were established and used to develop a
scoring system by mathematical methods based on linear pro-
gramming24 such that when all 6 core set measures are consid-
ered together, the maximum score (total improvement score)
possible for representing a patient's improvement is 100, and
the minimum score is 0.
We then compared the performance characteristics of the
drafted definitions in the patient profiles, using expert consensus
ratings as a gold standard, and externally validated the candidate
response criteria by applying them to clinical trial data. This
process led to the development of traditional categorical as well
as continuous candidate definitions for response criteria, with
thresholds for minimal, moderate, and major improvement.18
Continuous candidate definitions can also be considered hybrid
definitions, because the same definition can be used either as a
continuous outcome measure by using the total improvement
score or as a categorical outcome measure by using the thresh-
olds for minimal, moderate, and major improvement.
Candidate definitions were evaluated using consensus profile
ratings as the gold standard, by assessing sensitivity, specificity,
and area under the curve (AUC) to compare the performance of
these candidate definitions. Those that performed well in the
consensus profiles (sensitivity and specificity both ≥80%, AUC
≥0.9 for minimal, and AUC ≥0.8 for moderate and major
improvement, using IMACS or PRINTO core set measures1)
were externally validated. The PRINTO trial randomised
patients with new-onset juvenile DM to receive prednisone
alone (n=47) or prednisone combined with methotrexate or
cyclosporine (n=46 patients per treatment arm).13 χ2 analysis
was used to compare the percentages of patients meeting the
candidate definitions for response at the primary end point
(6 months) for the combined treatment arms versus the
prednisone-alone (placebo) arm. Definitions with a significant
difference (p<0.05) between treatment arms for minimal
improvement were further considered. Both PRINTO and
IMACS core set measures were available in this trial.
A second trial validation data set included 48 juvenile DM
patients enrolled in the Rituximab in Myositis (RIM) trial for
treatment-refractory patients. It had a randomised placebo-phase
design in which patients received either rituximab or placebo at
weeks 0 and 1, and at weeks 8 and 9 their treatment assignment
was reversed in a blinded manner.25 We used the
Mann-Whitney U test to determine whether each candidate def-
inition could differentiate between the treating physician’s
rating of improvement (score range 1–7) at 6 months, a time
point when most patients improved and that was also compar-
able to that in the PRINTO trial. For the RIM trial, only the
IMACS core set measures were available.
We then selected the top candidate definitions, up to 4 top-
performing definitions from each of the six different types of can-
didate definitions (table 1), for consideration at the final consensus
conference as a manageable number of definitions to discuss.
Consensus conference
Nominal group technique was used at a consensus conference
held in Paris, France on 9–10 June 2014, led by experienced
moderators (LGR and NR, for the paediatric working group)
The methodologies used to develop the new candidate response
criteria and performance characteristics of each type of candi-
date definition were reviewed with the participants in a general
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session. The 12 paediatric working group participants first inde-
pendently and then as a group reviewed the performance
characteristics of the 14 top candidate definitions of response
criteria for juvenile DM. Data for minimal, moderate, and
major clinical response were presented for each definition,
including a detailed spreadsheet that included the performance
in the patient profiles using the IMACS and PRINTO core set
measures, including sensitivity, specificity, AUC, as well as kappa
values and ORs. AUC was defined as the average of the sensitiv-
ity and specificity values for all categorical candidate definitions,
as well as for thresholds for minimal, moderate, and major
improvement in continuous candidate definitions. In addition,
for continuous definitions, an AUC for the total improvement
score was determined from the receiver operating characteris-
tic (ROC) curve as a plot of sensitivity versus (1—specificity)
for total improvement scores as well as for thresholds.26–28
Results of the external validation for each candidate defin-
ition from the PRINTO and RIM clinical trial data sets were
also presented.
Paediatric working group
After reviewing the performance of the 14 top performing can-
didate definitions, the 12 paediatric working group participants
developed consensus response criteria for minimal, moderate,
and major improvement in juvenile DM. The participants were
informed of the secondary goal of reaching consensus on
response criteria for both juvenile DM and adult DM/polymyo-
sitis (PM). Participants were first asked to rank their top five
choices, considering the data presented, based on face validity,
feasibility, and generalisability, and to determine which response
criteria were most clinically meaningful. The voting process
was conducted in a systematic manner with a predetermined
Table 1 Types of candidate definitions for response criteria that were developed and tested
Type of candidate
definitions of response Description Example of the candidate definition for the response criteria
Previously published
(categorical definition)
Previously published response criteria that were retested Minimal. Three of any 6 improved by ≥20%, no more than 1 worse by
>30% (which cannot be CMAS)10
Moderate. Three of any 6 improved by ≥50%, no more than 1 worse
by >30% (which cannot be CMAS)11
Major. Three of any 6 improved by ≥70%, no more than 1 worse by
>30% (which cannot be CMAS)11
Newly drafted
(categorical definition)
Drafted relative or absolute per cent change in candidate definitions
of response, based on recent CSM survey
Minimal. MD global, muscle strength (MMT or CMAS), and 1 other
CSM improved by ≥20%
Moderate. MD global, muscle strength (MMT or CMAS), and 1 other
CSM improved by ≥30%
Major. MD global, muscle strength (MMT or CMAS), and 1 other CSM
improved by ≥50%
Weighted
(categorical definition)
Applied conjoint analysis relative weights to CSM in newly drafted
definitions; each CSM receives improvement points (corresponding
relative weights) when it reaches the threshold for minimal, moderate,
or major improvement; worsening points are applied similarly;
improvement is calculated based on a total score of improvement vs
worsening
Improvement=at least 3.5 improvement points of 10 total improvement
points, and no more than 1.5 worsening points, where MD global=2
points, parent global=1 point, MMT/CMAS=3 points, C-HAQ=1.5
points, extramusc/DAS=1.5 points, enzyme/CHQ-PhS=1 point
Minimal. Improvement points given when CSM ≥20%; worsening
points given when CSM worse by >30%
Moderate. Improvement points given when CSM ≥50%; worsening
points given when CSM worse by >30%
Major. Improvement points given when CSM ≥75%; worsening points
given when CSM worse by >30%
Logistic regression
(continuous definition)
Model of improvement using a combination of CSM with different
weights, as developed in the logistic regression model; total scores
derived, with different cutoffs for minimal, moderate, and major
improvement
Relative % change
Improvement score=(MD global % change)+0.5×(parent global activity
% change)+0.5×(extramusc activity or DAS % change)
Minimal. Improvement score ≥15
Moderate. Improvement score ≥30
Major. Improvement score ≥60
CSM–weighted
(continuous definition)*
Multiply the % change in each CSM by the weights derived from
conjoint analysis, then sum (% change in each CSM×conjoint analysis
weights) to get final total improvement score; different thresholds for
minimal, moderate, and major improvement established based on
consensus profile ratings as gold standard
Improvement score=2×(MD global % change)+(parent global %
change)+3×(MMT or CMAS % change)+1.5×(C-HAQ % change)
+1.5×(extramusc or DAS % change)+(enzyme or CHQ-PhS % change)
Minimal. Improvement score ≥100
Moderate. Improvement score ≥250
Major. Improvement score ≥400
Conjoint analysis
(continuous definition)
For a given range in the level of improvement in each CSM, a score is
assigned, as developed by the survey results and modelling; greater
degrees of improvement receive higher scores; a patient is minimally
improved if the improvement score is above the cutoff for minimal
improvement; similarly for moderate and major improvement
Cut points for the model for juvenile DM are:
Minimal. Improvement score ≥30
Moderate. Improvement score ≥45
Major. Improvement score ≥70†
*This type of definition was not brought to the final consensus conference.
†The full absolute per cent change model is shown in table 3 and in online supplementary table S2 (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract).
C-HAQ, Childhood Health Assessment Questionnaire; CHQ-PhS, physical summary score of the Child Health Questionnaire–Parent Form 50; CMAS, Childhood Myositis Assessment Scale;
CSM, core set measure; DAS, Disease Activity Score; DM, dermatomyositis; enzyme, most abnormal serum muscle enzyme value among aldolase, alanine aminotransferase, aspartate
aminotransferase, lactate dehydrogenase, and creatine kinase; extramusc, extramuscular global activity; MD global, physician global activity score; MMT, manual muscle testing; parent
global, parent global activity score.
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format using nominal group technique29 30 facilitated by an
internet-based system developed by staff at the PRINTO coord-
inating centre.31 32 Voting was done anonymously and inde-
pendently using the online voting software.
After the initial round of voting, the results were shared with
the group. Each participant was then asked to explain his or her
top- and bottom-ranked choices to the group. The rounds of
voting continued in the same manner until consensus was
reached (≥80% of the votes) or until it was clear that consensus
would not be reached. Between each round, after the participants
were shown the results, the administrators were allowed to
remove candidate definitions that decisively received a small pro-
portion of the votes. In the final round, participants were asked
to select their final top response criteria. The paediatric working
group also voted on additional issues, including use of both
IMACS and PRINTO core set measures and response criteria for
juvenile DM that would interchange both the IMACS and
PRINTO measures. Participants also voted on retesting the per-
formance of the top candidate response criteria in future trials.
Combined paediatric and adult working group
After consensus was attained for juvenile DM response criteria,
a combined working group of 22 paediatric and adult experts
was formed to determine whether consensus could be reached
on final, common response criteria for both juvenile DM and
adult DM/PM. Common response criteria that would include
both juvenile DM and adult DM/PM were considered for use in
clinical trials, which might facilitate drug approvals for myositis
treatment. Experienced moderators (LGR, RA, FWM, and NR)
led the combined working group. For the first round of votes,
the top adult and paediatric definitions from the final round of
voting in each working group were considered. The online
voting system was utilised again, and each participant discussed
his or her top-choice candidate definition, using nominal group
technique in a round-robin manner. At each round, participants
were asked to select only one candidate top response croteroa
set; discussion was stopped once consensus of ≥80% was
reached. For determining the thresholds of improvement for the
selected definition, the required consensus was ≥70%, which
was done by post-conference voting.
RESULTS
The performance characteristics of 101 of 312 candidate defini-
tions were excellent (sensitivity and specificity of ≥80%, AUC
≥0.90 for minimal improvement), and 30 candidate definitions
also performed well in 2 clinical trials, in which they differen-
tiated between treatment arms (p<0.05 for minimal improve-
ment) and differentiated the treating physician’s improvement
score at week 24 (p<0.001).15
Top candidate definitions for response criteria
Fourteen top-performing candidate definitions were brought to
the paediatric working group for consideration at the consensus
conference (table 2 and online supplementary tables S1 and S2,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract). These
candidate criteria included nine categorical definitions in which
different criteria were set for minimal, moderate, and major
improvement and five continuous definitions in which improve-
ment points are given on a continuous scale that corresponds to
the magnitude of improvement, with different thresholds for
minimal, moderate, and major improvement. Among the nine
categorical definitions, two were previously published IMACS
and PRINTO response criteria,9–11 four were newly drafted
definitions based on a survey of experts, and three were weighted
definitions. Among the continuous definitions, two were devel-
oped by logistic regression, and three were developed from the
conjoint analysis survey. Among the 14 candidate criteria consid-
ered, 11 were based on relative per cent change, and 3 were
based on absolute per cent change in the core set measures.
The performance characteristics of these 14 candidate defini-
tions are shown in table 2 and online supplementary table S1
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract). In the
patient profiles, with expert consensus as a gold standard, all defi-
nitions presented at the conference had sensitivity and specificity
of ≥87% (AUC≥0.90) for minimal improvement (table 2 and
online supplementary table S1). For moderate improvement, speci-
ficity decreased but was ≥80% (AUC≥0.88), and for major
improvement specificity was generally ≥75% (AUC≥0.84). For
continuous definitions, the AUCs (from ROC curves) for the total
improvement score were generally better than the AUCs (average
of sensitivity and specificity) for the thresholds of minimal, moder-
ate, and major improvement. Performance was similar between the
IMACS and PRINTO core set measures for each definition.
Almost all candidate criteria were validated using the
PRINTO trial at 6 months, when they could differentiate
between treatment arms, with p<0.05 for minimal improve-
ment (table 2 and online supplementary table S1). All candidate
criteria were also validated in 48 juvenile DM patients in the
RIM trial.25 All definitions could differentiate the median treat-
ing physician’s improvement score at week 24 (p≤0.006).
Consensus conference voting
Among the 14 candidate definitions, 13 and 11 candidate defini-
tions of response were promoted in the first and second voting
rounds, respectively. In round three, six candidate definitions
were chosen, each receiving a similar number of votes. These
six included the three conjoint analysis–based continuous defini-
tions, a conjoint analysis–based weighted definition, a logistic
regression absolute per cent change definition, and the previ-
ously published PRINTO preliminary response criteria.8 9 In the
fourth round of voting and discussion, participants reached con-
sensus on final top response criteria, a conjoint analysis–based
continuous model using absolute per cent change in the IMACS
or PRINTO core set measures (table 3).
Table 2 and online supplementary table S1 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40060/abstract) show the performance
characteristics in the patient profiles and the trial validation for
each of the top candidate response criteria presented at the
conference. For the top conjoint analysis–based continuous
response criteria using absolute per cent change in each of the
core set measures, the sensitivity and specificity in the patient
profiles was generally >90% and the AUC >0.90 for both the
IMACS and PRINTO measures. For the PRINTO trial, a differ-
ence in the treatment arms was detected for minimal and mod-
erate improvement using the top response criteria, and in the
RIM trial a difference in the physician’s rating of improvement
when the response criteria rated the patient as improved versus
not improved was detected for minimal, moderate, and major
improvement.
Paediatric experts favoured the conjoint analysis–based con-
tinuous response criteria because of the continuous improve-
ment score that corresponds to the magnitude of improvement
and provides the ability to categorise a patient’s degree of
change into minimal, moderate, and major improvement. The
continuous model definitions also differentially weight the
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Table 2 Detailed performance characteristics of patient profiles for the top 5 candidate definitions presented at the consensus conference*
PRINTO trial§ RIM trial¶
Candidate definition type based
on final consensus rank order,
improvement category, CSM
Sensitivity,
%
Specificity,
% Threshold AUC†
Total
improvement
score AUC‡
Tx
(%)
Ctrl
(%) p Value
Response
criteria,
improved**
Response
criteria, not
improved# p Value Rank
Conjoint analysis, absolute %
change (model 3)††
1
Minimal (≥30)
IMACS 89 91 0.90 0.98 75 53 0.009 2.0 3.0 <0.001
PRINTO 89 98 0.93 0.99 73 55 0.038
Moderate (≥45)
IMACS 92 99 0.95 0.99 70 53 0.057 2.0 3.0 <0.001
PRINTO 94 94 0.94 0.99 71 51 0.023
Major (≥70)
IMACS 91 86 0.89 0.96 51 43 0.341 2.0 3.0 0.006
PRINTO 98 85 0.91 0.98 58 49 0.331
Conjoint analysis, relative %
change (model 1)‡‡
2
Minimal (≥33)
IMACS 99 87 0.93 0.98 75 55 0.018 2.0 4.0
PRINTO 96 98 0.97 1.00 74 55 0.027
Moderate (≥60)
IMACS 97 93 0.95 0.99 73 51 0.011 2.0 3.0 <0.001
PRINTO 97 96 0.96 1.00 70 51 0.032
Major (≥80)
IMACS 91 87 0.89 0.96 57 49 0.396 1.5 3.0 <0.001
PRINTO 98 86 0.92 0.97 61 49 0.179
Conjoint analysis, relative %
change (model 2)‡‡
3
Miminal (≥33)
IMACS 95 94 0.94 0.98 75 53 0.009 2.0 4.0 <0.001
PRINTO 94 98 0.96 0.99 74 55 0.027
Moderate (≥55)
IMACS 95 95 0.95 1.00 70 51 0.032 2.0 3.0 <0.001
PRINTO 97 98 0.98 1.00 70 51 0.032
Major (≥77)
IMACS 93 86 0.90 0.97 49 47 0.814 1.0 2.0 0.011
PRINTO 96 90 0.93 0.99 59 49 0.273
Weighted definition, relative %
change§§
4
Minimal (improvement points given
when CSM ≥20, worsening points
given when CSM worse by >30)
IMACS 95 100 0.97 NA 70 51 0.032 2.0 3.0 <0.001
PRINTO 92 98 0.95 NA 73 53 0.021
Moderate (improvement points
given when CSM≥50%, worsening
points given when CSM worse by
>30%)
IMACS 95 91 0.93 NA 68 51 0.045 2.0 3.0 <0.001
PRINTO 95 92 0.94 NA 71 51 0.023
Major (improvement points given
when CSM ≥75%, worsening points
given when CSM worse by >30%)
IMACS 100 81 0.91 NA 64 47 0.050 1.5 3.0 <0.001
PRINTO 98 85 0.91 NA 62 49 0.142
Continued
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various core set measures, which experts thought were consist-
ent with their assessment of the relative importance of each of
the core set measures. The top response criteria were based on
absolute per cent change in core set measures, which was also
favoured by the participants because, given the various visual
analog scale (VAS) measurements used in the core set measures,
the absolute per cent changes were more congruent than relative
per cent changes with actual changes that the myositis experts
see in clinical practice.
Final response criteria chosen by the combined pediatric
and adult working group
For this round of votes, the top 2 paediatric (table 2) and adult
definitions18 were considered. Two rounds of voting resulted in
final consensus response criteria, with 91% of participants voting
for the conjoint analysis–based continuous response criteria based
on absolute per cent change in the core set measures (table 3). It
was agreed that the top response criteria would be used in future
clinical trials that combined juvenile DM and adult DM/PM.
Because the final response criteria were similar, participants
favoured using response criteria that would be common to
juvenile DM and adult DM/PM, and they favoured combined
studies when possible as well as the possibility of comparing out-
comes in separate studies using the same final response criteria.
Other votes
In a post-conference final vote using the Delphi method, 74%
of the participants agreed to use the following paediatric thresh-
old values for minimal, moderate, and major response in juven-
ile DM: total improvement score ≥30 (on a scale of 0–100) for
minimal, ≥45 for moderate, and ≥70 for major improvement.
In contrast, the final thresholds for minimal, moderate, and
major response in adult DM/PM were ≥20, ≥40, and ≥60,
respectively. The paediatric working group also reached consen-
sus that, given the overall similarity between the IMACS and
PRINTO response criteria, joint IMACS/PRINTO response cri-
teria for juvenile DM are being proposed. The current develop-
ment of the response criteria in parallel between the IMACS
and PRINTO core set measures necessitates that either all of the
IMACS or all of the PRINTO core set measures be used. The
paediatric experts, however, committed to measure both IMACS
and PRINTO core set measures in future therapeutic trials, with
Table 2 Continued
PRINTO trial§ RIM trial¶
Candidate definition type based
on final consensus rank order,
improvement category, CSM
Sensitivity,
%
Specificity,
% Threshold AUC†
Total
improvement
score AUC‡
Tx
(%)
Ctrl
(%) p Value
Response
criteria,
improved**
Response
criteria, not
improved# p Value Rank
Previously published definition,10 11
relative % change
5
Minimal (3 of any 6 improved by
≥20%, no more than 1 worse by
>30%) (which cannot be MMT/
CMAS)10
IMACS 93 100 0.97 NA 70 51 0.032 2.0 3.0 <0.001
PRINTO 88 100 0.94 NA 71 51 0.023
Moderate (3 of any 6 improved by
≥50%, no more than 1 worse by
>30%) (which cannot be MMT/
CMAS)11
IMACS 90 95 0.93 NA 66 51 0.081 2.0 3.0 <0.001
PRINTO 90 96 0.93 NA 68 51 0.045
Major (3 of any 6 improved by
≥70%, no more than 1 worse by
>30%) (which cannot be MMT/
CMAS)11
IMACS 99 83 0.91 NA 63 49 0.111 2.0 3.0 <0.001
PRINTO 99 89 0.94 NA 60 49 0.223
*The performance characteristics of patient profiles for definitions ranked 6–14 are shown in online supplementary table S1 (available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract). Note that either International Myositis Assessment and Clinical Studies (IMACS) or Paediatric Rheumatology International Trials
Organisation (PRINTO) core set measures (CSMs) may be used in these candidate definitions of response; the candidate definitions were developed in parallel with IMACS or PRINTO
CSMs. Tx, treatment arm of prednisone in combination with methotrexate or cyclosporine; Ctrl, control; NA, not applicable.
†Calculated as the area under the curve (AUC) from the receiver operating characteristic (ROC) curve for the total improvement score and the threshold for minimal, moderate, and major
improvement.
‡Calculated as the AUC from the ROC curve, using the total improvement score and the threshold cutoffs for minimal, moderate, and major improvement, which applies only to
continuous definitions.
§PRINTO juvenile dermatomyositis (DM) trial of prednisone alone versus prednisone with methotrexate or cyclosporine (n=139).13
¶Rituximab in Myositis (RIM) trial juvenile DM arm (n=48). Comparison of the treating physician’s rating of improvement if the improvement criteria are met versus not met at week
24.25 A 1-point difference in physician’s rating of improvement from no improvement to minimal improvement was considered not only statistically significant but also clinically
significant.
**Median score for physician’s rating of improvement.
††The conjoint analysis–based continuous candidate response criteria using absolute per cent change in CSMs (absolute per cent change model) are shown in table 3. These criteria are
also the top response criteria for adult DM/polymyositis (PM), but with different thresholds for the total improvement score for minimal, moderate, and major improvement.18
‡‡The conjoint analysis–based continuous candidate definitions using relative per cent change in CSMs are shown in online supplementary table S3 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract). These criteria are also the second- and third-choice criteria for adult DM/PM, but with different
thresholds in the total improvement score for minimal, moderate, and major improvement.18
§§Improvement=at least 3.5 improvement points of 10 total improvement points, and no more than 1.5 worsening points, where physician global activity=2 points, parent global
activity=1 point, manual muscle testing (MMT) or Childhood Myositis Assessment Scale (CMAS)=3 points, Childhood Health Assessment Questionnaire=1.5 points, extramuscular global
activity or Disease Activity Score=1.5 points, and enzyme or physical summary score of the Child Health Questionnaire–Parent Form 50=1 point.
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92% agreement, and to continue to test the interchangeability
of the IMACS and PRINTO core set measures. The group also
unanimously agreed to retest the validity of the top five candi-
date definitions for response criteria and to utilise the other
four definitions as secondary end points in future clinical trials.
The top 3 of these criteria, the conjoint analysis definitions, are
the same for both juvenile DM and adult DM/PM, with different
thresholds of improvement (table 3 and online supplementary
table S3, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40060/abstract).
DISCUSSION
Conjoint analysis–based continuous response criteria, based on
absolute per cent change in the core set measures, were
Table 3 Final top response criteria for minimal, moderate, and major improvement in juvenile dermatomyositis (DM) and combined adult DM/PM
and juvenile DM clinical trials and studies*
Core set measure, level of improvement based on
absolute per cent change Improvement score
Physician global activity
Worsening to 5% improvement 0
>5% to 15% improvement 7.5
>15% to 25% improvement 15
>25% to 40% improvement 17.5
>40% improvement 20
Parent global activity
Worsening to 5% improvement 0
>5% to 15% improvement 2.5
>15% to 25% improvement 5
>25% to 40% improvement 7.5
>40% improvement 10
Manual muscle testing or CMAS
Worsening to 2% improvement 0
>2% to 10% improvement 10
>10% to 20% improvement 20
>20% to 30% improvement 27.5
>30% improvement 32.5
Childhood Health Assessment Questionnaire
Worsening to 5% improvement 0
>5% to 15% improvement 5
>15% to 25% improvement 7.5
>25% to 40% improvement 7.5
>40% improvement 10
Enzyme (most abnormal) or CHQ-PhS
Worsening to 5% improvement 0
>5% to 15% improvement 2.5
>15% to 25% improvement 5
>25% to 40% improvement 7.5
>40% improvement 7.5
Extramuscular activity or Disease Activity Score
Worsening to 5% improvement 0
>5% to 15% improvement 7.5
>15% to 25% improvement 12.5
>25% to 40% improvement 15
>40% improvement 20
The total improvement score is the sum of all 6 improvement scores associated with the change in each core set measure. A total improvement score of ≥30 represents
minimal improvement, a score of ≥45 represents moderate improvement, and a score of ≥70 represents major improvement.
*Either all of the International Myositis Assessment and Clinical Studies Group (IMACS) or all of the Paediatric Rheumatology International Trials Organisation (PRINTO) core set measures
may be used. Note that these response criteria are also proposed for use in combined adult dermatomyositis/polymyositis (DM/PM) and juvenile DM trials.18 For comparison, the
thresholds of improvement in the total improvement score for adult DM/PM are ≥20 for minimal improvement, ≥40 for moderate improvement, and ≥60 for major improvement.
How to calculate the improvement score: The absolute percent change ([final value − baseline value]/range × 100) is calculated for each core set measure. For muscle enzymes, the
most abnormal serum muscle enzyme level at baseline (creatine kinase, aldolase, alanine transaminase, aspartate aminotransferase, lactate dehydrogenase) is used. The enzyme range
was calculated based on a 90% range of enzymes from natural history data,5 38 which for creatine kinase is 15 times the upper limit of normal (ULN), for aldolase is 6 times the ULN, and
for lactate dehydrogenase, aspartate aminotransferase, and alanine transaminase is 3 times the ULN. The ULN is determined according to the individual laboratories in the participating
centers. The ranges for the other core set activity measures are based on the instrument scale used.13 15 25 An improvement score is assigned for each core set measure based on the
absolute percent change. These are totaled among the 6 IMACS or PRINTO core set measures. The thresholds for minimal, moderate, and major improvement are provided. The total
improvement score itself may also be compared among treatment arms in a trial. A total improvement score between 0 and 100 corresponds to the degree of improvement, with higher
scores corresponding to a greater degree of improvement.
CHQ-PhS, Physical Summary Score of the Child Health Questionnaire–Parent Form 50; CMAS, Childhood Myositis Assessment Scale; DAS, Disease Activity Score; MMT, manual muscle testing.
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developed as the consensus- and data-driven response criteria
for minimal, moderate, and major improvement in juvenile DM.
For the response criteria, either IMACS or PRINTO core set
measures could be used. In addition, it was agreed that the same
response criteria, using the IMACS core set measures but with
different thresholds for improvement, would be the consensus
response criteria for adult DM/PM trials and combined juvenile
DM and adult DM/PM trials in the future.18
The comprehensive process used to develop final response cri-
teria for minimal, moderate, and major improvement in juvenile
DM included the use of large, prospective, natural history data
sets for juvenile DM and data from two randomised controlled
trials for validation, which included a wide range of disease
activity and different stages of disease, from recently diagnosed
to treatment-refractory patients.13 15 25 The involvement of
many clinical experts who had experience using the core set
measures in juvenile DM patients was also critical. They pro-
vided input at several points throughout the process, including
determining thresholds for improvement in core set measures by
which definitions of response were drafted, achieving gold
standard ratings of improvement by evaluating and developing
consensus patient profiles, completing the conjoint analysis
surveys to develop differential weights for the core set measures,
and participating in the final consensus conference to achieve
consensus for common response criteria with the greatest clin-
ical face validity. The current response criteria (table 3) also
resolve the differences between PRINTO and IMACS core set
measures by testing candidate definitions of response criteria in
parallel using both sets of measures and showing that they are
largely interchangeable, and that their performance is compar-
able. Moreover, this project brought both IMACS and PRINTO
consortia to work together for this rare disease.
The combined group of paediatric and adult experts selected
the same top-choice definition but with differing thresholds for
improvement, which had very similar performance character-
istics and were thought to be more appropriate for use in clin-
ical trials that would, in the future, combine adult and
paediatric patients.
The final response criteria selected, conjoint analysis–based
continuous response criteria using absolute per cent change in
core set measures, have many advantages. For each measure,
improvement points are calculated based on the level of change
in that measure, and each core set measure is differentially
weighted, such that changes in muscle strength and physician
global activity are weighted more heavily than changes in the
most abnormal enzyme value or quality of life. A total improve-
ment score can be obtained as a continuous measure, and the
means or medians of total improvement scores can be compared
between treatment arms.33 A total improvement score between
0 and 100 also corresponds to the degree of improvement, with
higher scores corresponding to a greater magnitude of improve-
ment. This score may be more sensitive to change, resulting in
smaller trial sample sizes.33 34 Alternatively, thresholds for
minimal, moderate, and major improvement have been estab-
lished that allow dichotomous use of the response criteria as
well. Therefore, this is truly a hybrid model that can be used as
either a continuous or categorical outcome measure within the
same response criteria depending on the trial design and needs
of the study.
The response criteria allow input from all the core set mea-
sures instead of relying on only a few measures to determine
whether a patient has experienced improvement. However,
although these response criteria were developed using all six
core set measures, the response criteria could still be used if
fewer core set measures were obtained, allowing for greater
flexibility in the types of patients and improvements that can
occur, but we caution that the response criteria are most
accurate when all six core set measures are used. As such,
the response criteria signify a major advance in assessing
improvement in therapeutic trials and other clinical research
studies by providing data-driven response criteria that were
developed by consensus of major stakeholders in the field who
come from all over the world.
Prior response criteria in rheumatic diseases have included33 34
relative per cent change,35 36 whereas myositis response criteria
are based on absolute per cent change. The experts favoured the
use of absolute per cent change for various reasons. In this
study, several core set measures used a 10-cm VAS, and the
experts thought that absolute per cent change better represents
the degree of change they see in clinical practice. Moreover,
absolute per cent changes can be calculated when the baseline
core set measure is 0 and give similar results for similar degrees
of change at either end of the VAS.
The participants also favoured using the same response cri-
teria for juvenile DM and adult DM/PM, but with cut points or
thresholds for improvement specific to paediatric or adult
patients. Having common response criteria facilitates the poten-
tial to conduct combined clinical trials, such as the RIM trial,25
and to compare the outcomes of trials and studies conducted
separately. Participants agreed to include other top-performing
definitions that were highly rated as secondary end points for
future clinical trials. Among these were not only other conjoint
analysis–based continuous models but also the published
PRINTO preliminary response criteria.10 11 Future work should
also evaluate whether a baseline composite score threshold
derived from the PRINTO or IMACS core set measures could
be used as inclusion criteria for future clinical trials.
Limitations of the present work include the lack of a placebo
group in the RIM trial. For this reason, the physician’s assess-
ment of improvement at 6 months was used instead. We were
fortunate to have another controlled clinical trial for juvenile
DM that had three treatment arms to use for external
validation,13 in which we evaluated the ability of the
candidate definitions to differentiate between treatment arms.
Although thresholds for major improvement were developed and
validated in fewer patients, we believe that it was sufficient given
that 29% of patients had major improvement in patient profiles,
and 17% had major improvement in the clinical trials used for
validation. The final conjoint analysis–based continuous response
criteria also do not address worsening in the core set measures;
however, this generally does not affect the outcome, because
when patients are rated as improved, no more than 1 or 2 mea-
sures worsen in our clinical data sets. Also, although we tested
the interchange of IMACS and PRINTO core set measures, we
tested these variations as 2 parallel core set measures but did not
examine intermixing the PRINTO and IMACS core set mea-
sures. Further work to examine the interchangeability of the
IMACS and PRINTO core set measures will be needed.
The data sets used to develop the new response criteria primar-
ily contained information about patients with a recent diagnosis
or those experiencing a disease flare, and further work is needed
to determine how the response criteria perform in patients with
longstanding disease or those with significant disease-related
damage. Finally, although application of the criteria might seem
cumbersome, as regularly done for JIA and RA, the evaluation of
improvement will be facilitated by appropriate dedicated software
or ‘apps’, or in the future, by simplification of the manner in
which the core set measures are evaluated (eg, similar to the
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Juvenile Arthritis Disease Activity Score for JIA).37 The time
required to apply these criteria is estimated to be 25–35 min to
complete the core set measures at each visit1 and 2–3 min to
hand-calculate the total improvement score and degree of
response. Both IMACS and PRINTO are developing a web-based
tool as well as a downloadable calculator that will allow easy
administration of the response criteria and immediate calculation.
The apparent complexity is, however, counterbalanced by the
establishment of different validated levels of improvement, which
constitute the real novelty of this project and which have never
been validated as such for either RA or JIA, despite being regu-
larly reported in clinical trials.
In summary, conjoint analysis–based continuous response cri-
teria that establish different thresholds for minimal, moderate,
and major improvement and utilise the absolute per cent change
in core set measures were chosen as the consensus response cri-
teria for juvenile DM and were validated using both natural
history and trial data. These response criteria should be highly
acceptable and widely used given that they were developed with
consensus among many myositis experts worldwide. They
should be sensitive in detecting differences in improvement and
in quantitating the degree of improvement, as seen in the two
clinical trials. Thus, clinical trials that test new therapies for
juvenile DM should be easier to design, conduct, and compare.
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